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The aim of this study was to address whether deficits in the central cholinergic activity
may contribute to the increased difficulty to allocate attention during gait in the elderly
with heightened risk of falls. We recruited 50 participants with a history of two or
more falls (33 patients with Parkinson’s Disease and 17 older adults) and 14 non-
fallers age-matched adults. Cholinergic activity was estimated by means of short
latency afferent inhibition (SAI), a transcranial magnetic stimulation (TMS) technique that
assesses an inhibitory circuit in the sensorimotor cortex and is regarded as a global
marker of cholinergic function in the brain. Increased difficulty to allocate attention
during gait was evaluated by measuring gait performance under single and dual-task
conditions. Global cognition was also assessed. Results showed that SAI was reduced
in patients with PD than in the older adults (fallers and non-fallers) and in older adults
fallers with respect to non-fallers. Reduction in SAI indicates less inhibition i.e., less
cholinergic activity. Gait speed was reduced in the dual task gait compared to normal
gait only in our faller population and changes in gait speed under dual task significantly
correlated with the mean value of SAI. This association remained significant after
adjusting for cognitive status. These findings suggest that central cholinergic activity
may be a predictor of change in gait characteristics under dual tasking in older adults
and PD fallers independently of cognitive status.
Keywords: Parkinson’s disease, dual task gait, falls, transcranial magnetic stimulation (TMS), cholinergic system,
attention
INTRODUCTION
Falls are a major cause of morbidity among older adults and individuals with neurodegenerative
diseases, such as Parkinson’s disease (PD). One potential mechanism underlying the increased
fall risk in those populations is reduced attentional resource allocation, which can compromise
postural and gait stability (Montero-Odasso et al., 2012). Although walking has long been
Abbreviations: MEPs, motor evoked potentials; MoCA, Montreal Cognitive Assessment; PD, Parkinson’s disease;
SAI, short latency afferent inhibition; TMS, transcranial magnetic stimulation.
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considered a primarily automatic motor task, emerging evidence
suggests that this view is overly simplistic (Hausdorff et al.,
2005; Amboni et al., 2013). Almost 20 years ago, the seminal
‘‘stops walking while talking’’ study by Lundin-Olsson et al.
(1997) showed that the inability to maintain a conversation
while walking is a marker of future falls in older nursing home
residents. Since then, many studies have used the ‘‘dual-task
paradigm’’ (i.e., observing people walking while they perform a
secondary attention-demanding task) to assess the interactions
between cognition (specifically reduced capacity to sustain and
divide attention), gait and propensity to fall. It is well known
that, the cholinergic system plays a vital role in the top-down
control of attentional orienting and stimulus discrimination
(Klinkenberg et al., 2011). Thus, a dysfunction of the cholinergic
system has been identified as potentially contributing to the
increased fall propensity and reduced attentional capacity in
aging and neurodegeneration. Recent imaging data support the
relationship between central cholinergic activity and falls and
slower gait speed in patients with PD (Bohnen et al., 2009, 2013).
Further, an association between cholinergic dysfunction and gait
disturbances in older adults with moderate to severe cognitive
impairment has been reported (Morris et al., 1987; Montero-
Odasso et al., 2015). Recent pilot work intriguingly suggested that
treatment with anti-cholinergic medications may the risk of falls
(Mancini et al., 2015; Henderson et al., 2016).
To date, however, it is not clear if cholinergic activity
is abnormal in PD fallers or elderly fallers, without clinical
diagnosis of dementia or other severe cognitive impairment,
and if this contributes to dual task gait disturbances, a marker
of fall risk.
To this aim, we assessed central cholinergic activity by
means of short latency afferent inhibition (SAI), a transcranial
magnetic stimulation (TMS) technique (Tokimura et al., 2000)
in two groups of ‘‘fallers’’ (older adults and patients with
PD), and a control group of older adults non-fallers. SAI
is thought to be related to central cholinergic activity, given
that in normal subjects it can be reduced or abolished by
muscarinic antagonist scopolamine (Di Lazzaro et al., 2000). To
explore the possible contribution of cholinergic activity to gait
dysfunction, we assessed gait speed under single and dual-task
conditions.
MATERIALS AND METHODS
Participants
This cross-sectional study involved 64 participants recruited
at the Department of Neuroscience, University of Genoa.
Particularly, this study involved 50 participants recruited for the
V-TIME study and 14 additional participants (Mirelman et al.,
2013).
Three age-matched groups of participants were included:
(i) 33 PD fallers (PD-F, 17 males and 16 females); (ii) 17 older
adults fallers (OLD-F, 7 males and 10 females); and (iii) 14 older
adults non-fallers (OLD-NF, 9 males and 5 females; Table 1).
Participants were considered as ‘‘fallers’’ if they reported two
or more falls within the 6 months prior to the beginning of
the study. Common inclusion criteria were: (i) age between
60 and 85 years and (ii) able to walk for 5 min unassisted.
Patients with PD were included if they had idiopathic
PD, as defined by the UK Brain Bank criteria, were in
Hoehn and Yahr stage II-III, and were medically stable for
at least 1 month prior to the study. Common exclusion
criteria were: (i) a clinical diagnosis of dementia or other
severe cognitive impairment (MMSE <24); (ii) psychiatric
co-morbidity; and (iii) history of stroke or other neurologic
disorders. All evaluations were performed in the morning
approximately 90 min after the first dopaminergic drugs intake
or when PD patients were in their best ‘‘on’’ medication
state. The experimental protocol was approved by the
Ethics committee of the University of Genoa (141/12).
Prior to any procedures, the study was fully explained to
the participants and written informed consent was obtained
from all subjects.
Assessment
For PD patients, disease severity was evaluated using the
Movement Disorders Society (MDS) Unified Prkinson’s
Disease Rating Scale (UPDRS) section III (Motor Examination)
and levodopa (L-DOPA) equivalent dose was calculated for
each patient. In all participants, global cognitive function
was evaluated with the Montreal Cognitive Assessment
(MoCA).
Participants were asked to walk in a well-lit corridor
under two conditions, each lasting 1 min: (i) walking at a
comfortable speed, (ii) walking during a verbal fluency task.
The GaitRite mat, a sensorized 7-meter carpet (CIR Systems,
Inc. Haverton, MA, USA), captured individual footfall data
using embedded pressure sensors. The ProtoKinetics Movement
Analysis Software was used to analyze the data. Gait speed was
determined.
Short Latency Afferent Inhibition (SAI)
Subjects were seated in a comfortable chair with a mounted
headrest during the experiments. Electromyography was
recorded with silver disc surface electrodes placed on a tendon
belly arrangement over the bulk of the first dorsal interosseus
muscle and the first metacarpophalangeal joint bilaterally.
Electromyography signals were amplified and filtered (20
Hz to 1 kHz) with a D360 amplifier (Digitimer). The signals
were sampled at 5000 Hz, digitized using a laboratory interface
(Power1401; Cambridge Electronics Design), and stored
on a personal computer for display and later offline data
analysis.
TMS was performed with a figure-of-eight coil connected
to a Magstim 2002 magnetic stimulator (Magstim, UK). The
coil was placed tangentially to the scalp with the handle
pointing backwards and laterally at a 45◦ angle to the sagittal
plane inducing a posterior–anterior current in the brain. We
determined the ‘‘motor hot spot’’ for activation of the first
digital interosseeus. At the beginning of each experiment, the
stimulus intensity needed to evoke motor evoked potentials
(MEPs) of approximately 0.8–1.0 mV peak-to-peak amplitude
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TABLE 1 | Demographics and clinical characteristics of participants.
PD patients fallers Older adults fallers Older adults non-fallers P Post hoc
(mean ± SD) (mean ± SD) (mean ± SD) (Mann Whitney)
Age (years) 72.6 ± 4.4 73.4 ± 4.2 72.1 ± 4.9 >0.05 –
Male/Female 17/16 7/10 9/5 >0.05
Education (years) 9.8 ± 4.6 11.2 ± 4.4 10.8 ± 4.1 >0.05 –
UPDRS III (score) 30.3 ± 9.13 – – – –
LEDD (mg) 775.5 ± 358.6 – – – –
Falls in 6 months prior to study (number) 3.8 ± 2.1 2.6 ± 1.0 – 0.031 –
MoCA (score) 23.7 ± 3.9 26.4 ± 1.6 28.3 ± 2.0 <0.000 §p = 0.006
#p < 0.000
∞p = 0.012
PD-F, Parkinson’s Disease fallers; OLD-F, Older adults fallers; OLD-NF, Older adults non fallers; UPDRS, Unified Parkinson’s Disease Rating Scale; LEDD, Levodopa
Equivalent Daily Dose; MoCA, Montreal Cognitive Assessment; Post hoc: §PD-F vs. OLD-F; #PD-F vs. OLD-NF; ∞OLD-F vs. OLD-NF.
was defined. MEPs were recorded from the more affected
side in PD patients and from the dominant side in the older
adults.
SAI was tested with a suprathreshold test TMS stimulus
over the hand area, adjusted to produce MEPs of 1 mV in
amplitude, preceded by an electrical conditioning stimulus over
the contralateral median nerve at the wrist (cathode proximal,
constant square wave current, duration 200 microseconds (200
µs), intensity set just above threshold for evoking a small twitch
in the opponens pollicis muscle). SAI was randomly tested at
six different inter-stimulus intervals, with 15 trials at each inter-
stimulus interval (conditioned trials: at 18, 20, 22, 24, 26 and
28 ms) and with 20 unconditioned (test) stimuli also delivered
randomly.
Data Analyses
Regarding gait parameters, gait speed was calculated under
normal and dual task gait and expressed inmeters/seconds (m/s).
To evaluate changes in gait speed induced by dual task with
respect to single task, a delta value was calculated as follows: (gait
speeddual task−gait speedsingle task)/gait speedsingle task) × 100. For
TMS, the amplitude of the conditioned responses was expressed
as a percentage of the amplitude of the test response.We averaged
the percentage of inhibition of the conditioned responses at the
six different inter-stimulus intervals to obtain a grand mean of
SAI.
Statistical Analyses
Gender differences between the groups were assessed by
Chi-square test. We checked that data were normally distributed
(Shapiro-Wilk W test). Differences between groups for age,
education and MoCA were assessed by the non-parametric
Kruskall-Wallis test and post hoc comparisons were done with
the Mann-Whitney U-test. Differences between OLD-F and
PD-F for number of falls over the past 6 months were assessed
by means of an unpaired t-test. Gait speed under single and
dual-task conditions were entered in a repeated measures
ANOVA (RM-ANOVA) with the factor GROUP as between
subjects factor and the factor CONDITION (normal and dual-
task gait) as the within subjects factor. Grand mean of SAI
was compared groups by means of a one-way ANOVA. The
correlation between dual task costs for gait speed and the grand
mean of SAI was evaluated by means of Spearman correlation
analysis. The level of significance was set at p < 0.05, post hoc
analysis was performed using t tests, applying the Bonferroni
correction for multiple comparisons where appropriate. To
assess whether cortical cholinergic activity was an independent
predictor of change in gait characteristics under dual task
condition, a stepwise linear regression model was constructed
adjusted for age and MoCA score. A standard statistical
package computed odds ratios (ORs), two-sided 95% confidence
intervals (CIs) and p values; p < 0.05 was considered to
be significant. All statistical analyses were performed using
SPSS22.
RESULTS
The demographic, clinical and cognitive data are summarized
in Table 1. There were no significant differences between age,
gender and education levels in the three groups (p > 0.05).
Number of falls over the past 6 months was significantly higher
in PD-F than in OLD-F (p = 0.03). For MoCA there was a
significant difference among the groups (p < 0.001). Post hoc
analysis revealed a significant difference between PD-F and
OLD-F with respect to OLD-NF and also between PD-F and
OLD-F (Table 1).
For gait speed (Figure 1), RM-ANOVA showed a significant
main effect of CONDITION (F(1,61) = 25.89; p < 0.001)
and GROUP (F(2,61) = 14.91;p < 0.001) and a significant
GROUP × CONDITION interaction (F(2,61) = 3, 29; p = 0.04).
During usual walking, gait speed was significantly lower in
PD-F than in OLD-NF (p < 0.001) and in OLD-F than in
OLD-NF (p = 0.003) with no difference between PD-F and
OLD-F (p = 0.12). During dual task walking, gait speed was
significantly lower in PD-F than in both OLD-F (p = 0.025)
and OLD-NF (p < 0.001) and in OLD-F than in OLD-
NF (p = 0.005). Consistent with this, PD-F and OLD-F
significantly reduced their gait speed under dual task gait with
respect to normal gait (PD-F, dual vs. normal p < 0.001;
OLD-F, dual vs. normal p = 0.022), whereas OLD-NF did
not significantly reduced gait speed under dual task gait
(p = 0.18).
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FIGURE 1 | Gait speed (m/s) under normal gait and dual task gait in the
three groups of subjects (Parkinson’s Disease fallers, PD-F; Older
adults fallers, OLD-F; Older adults non-fallers, OLD-NF). Asterisks
indicate statistical significant difference within group between normal and dual
task gait (∗p < 0.05, ∗∗p < 0.01).
SAI results are reported in Figure 2A. One way-ANOVA
showed a significant effect of GROUP (F(2,61) = 12.15; p< 0.001),
There was significant less SAI in PD-F than in OLD-F (p = 0.010)
and OLD-NF (p < 0.001), and in OLD-F than in OLD-NF
(p = 0.045; Figure 2B). Further, the dual task change in gait
speed was significantly correlated with the grand mean of
SAI in our population (Rho = −0.39, p = 0.001; Figure 3);
subjects who had lower cortical cholinergic activity, tended to
have a greater decrease in gait speed during the dual task
gait.
Univariate linear regression analysis showed that the
significant association between the grand mean of SAI and
gait speed change induced by dual task condition remained
significant after adjusting for age and MoCA score (Table 2).
DISCUSSION
The main results of the present study were the following: First,
we found that our faller population manifested a cholinergic
dysfunction with respect to older adults non-fallers. Second,
change in gait speed in the dual task condition significantly
correlated with cholinergic dysfunction, suggesting that subjects
with lower central cholinergic activity were more likely to have
a larger decrease in gait speed induced by dual task. Finally,
we found that central cholinergic activity was an independent
predictor of change in gait characteristics under dual task
in our faller population regardless of cognitive status even
if, as expectable, older adults performed better than PD on
MoCA.
Strong evidence supports that SAI is a cholinergic-
dependent marker of intra-cortical excitability. This
neurophysiological technique has been already used in the
context of pathophysiology understanding in both Parkinson’s
disease and healthy aging. Previous works in PD suggested
that central cholinergic activity is abnormal already in the early
stages of disease, contributing to initial gait worsening under
normal gait (Rochester et al., 2012) and to cognitive disturbances
(Yarnall et al., 2013). Evidence in healthy aging, instead,
linked central cholinergic activity to cognitive disturbances
(Young-Bernier et al., 2012), but not yet to gait disturbances
or falls.
Several previous studies support the ‘‘cholinergic hypothesis’’
of age-related cognitive decline (Bartus et al., 1982) by correlating
imaging-derived measures of basal forebrain cholinergic
structural decline with lower performance in older adults
(Düzel et al., 2010; Hall et al., 2011; Wolf et al., 2014). In PD,
the loss of basal forebrain cholinergic neurons and associated
cortical cholinergic innervation is more extensive than in
the brain of older adults and when patients with PD also
develop dementia, cholinergic loss progresses most severely
(Bohnen et al., 2003, 2006, 2012; Sarter et al., 2014). In addition,
neuropathological studies have reported that almost 50%
of the large cholinergic neurons of the pedunculopontine
nucleus degenerate in PD (Pahapill and Lozano, 2000). Beyond
showing cholinergic hypo-function both in aging and PD,
experimental evidence on cholinergic decline in animal models
and humans showed a close relationship between loss of
cholinergic neurons and impairments in attention (Sarter
and Bruno, 1998; Bohnen et al., 2006; Schliebs and Arendt,
2011).
The dual task paradigm is an optimal test for investigating
the interplay between attention and motor control (O’Shea
et al., 2002). The dual task deterioration of performance
observed in our faller population, indicates that walking in
our faller groups apparently required a heightened attentional
control, likely because of a loss of automaticity. Indeed, a
hallmark of normal control of walking is automaticity, which
is the ability of the nervous system to successfully coordinate
movement with minimal use of attention-demanding control
resources (Clark, 2015). Performance of automated motor skills
only requires minimal attentional demands, and needs little
capacity resources, but if a motor skill is not automatic, it
must utilize considerable attention and neural resources (Wu
et al., 2015). In order to maintain normal walking movements,
our faller population apparently tended to use attentional
control strategies to bypass impaired automatic control, as
evidenced by the sensitivity to dual tasking, and therefore, more
attentional resources were needed. Perhaps this explains why
attentional resources were not enough to sufficiently support
the performance of the gait task properly during dual tasking.
Here we showed that cholinergic dysfunction might be the
neurophysiological substrate of a reduced ability to allocate
attention, reduced gait monitoring during dual task and thus
heightened risk of falls.
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FIGURE 2 | Results from short latency afferent inhibition (SAI). (A) Time course of inhibition. Abscissa indicates the interstimulus intervals (ISIs) whereas
ordinate indicates the size of the conditioned response, expressed as a percentage of the unconditioned motor evoked potentials (MEPs). (B) Grand mean of SAI
calculated by combining across all interstimulus intervals (ISIs) the conditioned responses and expressed as the percentage of the unconditioned MEPs. Asterisks
indicate significant between groups difference (∗p < 0.05, ∗∗p < 0.01). PD-F, Parkinson’s Disease fallers; OLD-F, Older adults fallers; OLD-NF, Older adults non fallers.
TABLE 2 | Regression model statistics and coefficients of variables for
dual task cost for walking speed (PD, OLD-F and OLD-NF).
Gait speed change DT P Stand. β R2 95% CI
SAI mean <0.001 −0.46 0.22 [−39.0, −13.7]
Adjusted for age <0.001 −0.47 0.23 [−39.6, −14.3]
Adjusted for age, MoCA 0.015 −0.34 0.27 [−34.8, −3.9]
PD-F, Parkinson’s Disease fallers; OLD-F, Older adults fallers; OLD-NF, Older adults
non-fallers; SAI, short latency afferent inhibition; DT, dual task; MoCA, Montreal
Cognitive Assessment.
To explain the causal role of cholinergic hypo-function
in aging and PD in inducing impairments in attention and
thus increased risk of falls, an intriguing hypothesis has
been suggested by Sarter et al. (2014). The authors proposed
that when the loss of cortical cholinergic inputs impairs
the attentional processing of gait, the striatal circuitry is
‘‘deprived’’ of this information, which it would normally use
to select and sequence motor actions. In other words, dual
cholinergic–dopaminergic loss attenuates the supervision of
striatal circuitry and thereby ‘‘unmasks’’ the consequences of
striatal dopaminergic denervation on gait (St. Peters et al.,
2011).
There are some study limitations that should be
acknowledged. First, cholinergic activity was evaluated at rest
with sitting position. This is indeed a good and reliable method to
FIGURE 3 | Correlation between the grand mean of SAI (X-axis) and the
% change in gait speed (gait speed) from normal to dual task (Y-axis).
The % change in gait speed was calculated as (gait speeddual task−gait
speedsingle task)/gait speedsingle task) × 100. Data of PD (white circles), older
adults fallers (OLD-F: gray circles) and older adults non-fallers (OLD-NF: black
circles) are plotted together.
measure cholinergic activity, as demonstrated by the fact that SAI
is reduced or even abolished with administration of a selective
muscarinic cholinergic receptor blocker in healthy participants
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(Di Lazzaro et al., 2000) and is reduced in Alzheimer’s disease
(Di Lazzaro et al., 2002) and in other disorders characterized by
cholinergic dysfunction (Di Lazzaro et al., 2007). However, it
is worthwhile to address that recent studies showed that SAI is
reduced in those muscles involved in a specific motor task during
movement (Voller et al., 2006; Asmussen et al., 2013, 2014).
In more details, decrease in SAI recorded during movement
preparation was primarily mediated by supraspinal mechanisms,
whereas both supraspinal and spinal mechanism contributed to
SAI reduction during movement (Asmussen et al., 2013, 2014).
These reductions in SAI when a muscle is involved in the task
have been supposed to be necessary to allow somatosensory
input to increase activity in the area of M1 responsible for the
desired motor output (Asmussen et al., 2014).
In the present study we linked cholinergic dysfunction,
as assessed by SAI, with motor performance deterioration
under dual task (gait speed decrement). In this vein, it might
be interesting in future studies to directly study whether an
abnormal movement-induced modulation of SAI is present in
fallers (either older adults and PD patients) and contributes to
motor performance deterioration.
Second, in this study, we did not plan to test whether
anticholinergic drugs may improve cholinergic activity as tested
by SAI in our faller population. To date, a randomized, double-
blind, cross-over trial is active in recruiting PD patients with the
aim of examining the effects of augmentation of the cholinergic
system on balance and gait (Mancini et al., 2015). Whether
anticholinergic drugs may normalize cholinergic activity should
be addressed in future study.
CONCLUSION
Our findings suggest that central cholinergic activity may
contribute to dual task gait disturbances, in older adults and
PD fallers. Taking into account that dual task gait disturbance
has been associated with fall risk, our findings give a strong
rationale to use cholinergic therapy in the management of
mobility problems in PD and in healthy aging, when fall risk is
high.
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